Wealthquest Corp Raises Position in Johnson & Johnson (NYSE:JNJ)

Wealthquest Corp lifted its stake in Johnson & Johnson (NYSE:JNJ) by 0.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,774 shares of the company’s stock after buying an additional 121 shares during the period. Wealthquest Corp’s holdings in Johnson & Johnson were worth $2,009,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of JNJ. Houlihan Financial Resource Group Ltd. acquired a new stake in Johnson & Johnson during the fourth quarter valued at approximately $1,376,000. Bowen Hanes & Co. Inc. raised its position in shares of Johnson & Johnson by 11.5% during the 4th quarter. Bowen Hanes & Co. Inc. now owns 362,432 shares of the company’s stock worth $52,868,000 after purchasing an additional 37,290 shares during the period. Community Financial Services Group LLC raised its position in shares of Johnson & Johnson by 2.6% during the 4th quarter. Community Financial Services Group LLC now owns 25,571 shares of the company’s stock worth $3,730,000 after purchasing an additional 645 shares during the period. Csenge Advisory Group raised its position in shares of Johnson & Johnson by 18.7% during the 4th quarter. Csenge Advisory Group now owns 13,480 shares of the company’s stock worth $1,966,000 after purchasing an additional 2,127 shares during the period. Finally, Grandfield & Dodd LLC raised its position in shares of Johnson & Johnson by 1.8% during the 4th quarter. Grandfield & Dodd LLC now owns 98,632 shares of the company’s stock worth $14,387,000 after purchasing an additional 1,720 shares during the period. 69.30% of the stock is owned by institutional investors.

JNJ has been the topic of a number of research reports. Raymond James increased their price target on Johnson & Johnson from $147.00 to $161.00 and gave the stock an “outperform” rating in a research report on Thursday, January 23rd. Cantor Fitzgerald reiterated a “buy” rating and set a $168.00 price target on shares of Johnson & Johnson in a research report on Thursday, January 23rd. Morgan Stanley upgraded Johnson & Johnson from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $145.00 to $170.00 in a research report on Tuesday, December 17th. Credit Suisse Group dropped their price target on Johnson & Johnson from $170.00 to $159.00 and set an “outperform” rating on the stock in a research report on Friday, March 6th. Finally, Citigroup initiated coverage on Johnson & Johnson in a research report on Wednesday, March 4th. They set a “buy” rating and a $163.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $162.33.

In other news, COO Michael E. Sneed sold 58,128 shares of the stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $149.39, for a total value of $8,683,741.92. Following the completion of the sale, the chief operating officer now owns 107,511 shares in the company, valued at $16,061,068.29. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director William D. Perez bought 500 shares of Johnson & Johnson stock in a transaction dated Friday, March 13th. The stock was acquired at an average price of $127.69 per share, with a total value of $63,845.00. Following the acquisition, the director now directly owns 16,030 shares of the company’s stock, valued at $2,046,870.70. The disclosure for this purchase can be found here. 0.27% of the stock is currently owned by corporate insiders.

JNJ stock traded up $0.22 on Wednesday, reaching $119.40. The company’s stock had a trading volume of 13,982,268 shares, compared to its average volume of 10,152,633. Johnson & Johnson has a 52 week low of $109.16 and a 52 week high of $154.50. The company has a market capitalization of $293.00 billion, a P/E ratio of 17.61, a price-to-earnings-growth ratio of 1.85 and a beta of 0.74. The firm has a fifty day moving average of $140.69 and a two-hundred day moving average of $138.34. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.26 and a quick ratio of 1.01.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, January 22nd. The company reported $1.88 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.87 by $0.01. The firm had revenue of $20.75 billion during the quarter, compared to analyst estimates of $20.83 billion. Johnson & Johnson had a return on equity of 39.27% and a net margin of 22.18%. The firm’s quarterly revenue was up 1.7% on a year-over-year basis. During the same period last year, the company posted $1.97 EPS. As a group, equities analysts expect that Johnson & Johnson will post 9.03 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 25th were given a dividend of $0.95 per share. The ex-dividend date was Monday, February 24th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 3.18%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 43.78%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Further Reading: Why do companies engage in swaps?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.